xM

JSON twin: https://www.healthaidb.com/software/xm.json

Company Name

Tempus

Product URL

https://www.tempus.com/oncology/genomic-profiling/xm/

Company URL

https://www.tempus.com

Categories

• diagnostic Support
• oncology Care
• clinical Decision Support
• Diagnostic
• Oncology
• Immunotherapy Monitoring

Summary

xM is a liquid biopsy assay developed by Tempus to monitor immunotherapy response in patients with advanced solid tumors, enabling early detection of molecular responses to immune-checkpoint inhibitors.

Description

xM is a liquid biopsy assay developed by Tempus to monitor immunotherapy response in patients with advanced solid tumors, enabling early detection of molecular responses to immune-checkpoint inhibitors. It quantifies changes in circulating tumor DNA (ctDNA) from blood samples, providing early molecular response assessments for patients undergoing ICI therapies. The assay leverages a multi-parametric algorithm integrating copy number variations (CNVs) and somatic and germline variant allele frequencies (VAFs) to estimate circulating tumor fraction. xM is currently available for research use only, with clinical availability expected later this year. ([investors.tempus.com](https://investors.tempus.com/news-releases/news-release-details/tempus-introduces-xm-assay-monitor-immunotherapy-response?utm_source=openai))

Api Available

yes

Certifications

• FDA 510(k)
• CE/MDR
• ONC
• ISO 13485

Company Founding

2015

Company Offices

• United States
• Canada
• United Kingdom
• Germany
• France
• Italy
• Spain
• Australia
• Japan
• China

Compliance

• HIPAA
• GDPR
• HITECH
• SOC 2
• ISO 27001

Customers

Data Residency

US/EU regions

Data Standards

• FHIR
• HL7 v2
• DICOM
• SNOMED
• ICD-10

Deployment Model

• SaaS
• on_prem
• hybrid

Features

• Liquid biopsy assay for monitoring immunotherapy response in advanced solid tumors
• Quantifies changes in circulating tumor DNA (ctDNA) from blood samples
• Enables early molecular response assessment in patients receiving immune-checkpoint inhibitors (ICI)
• Utilizes a multi-parametric algorithm integrating copy number variations (CNVs) and variant allele frequencies (VAFs)
• Provides tumor-informed minimal residual disease (MRD) monitoring
• Offers tumor-naive MRD testing for colorectal cancer recurrence monitoring
• Delivers rapid results from a single blood draw
• Seamlessly integrates into routine clinical practices
• Supports personalized treatment plans based on molecular response
• Enhances early detection of disease progression
• Improves patient outcomes through timely therapeutic adjustments
• Facilitates non-invasive monitoring of treatment efficacy
• Reduces the need for invasive biopsy procedures
• Provides quantitative ctDNA status calls (detected/not detected)
• Offers quantitative results for precise monitoring
• Supports integration with electronic health records (EHR) systems
• Compatible with various laboratory information management systems (LIMS)
• Provides comprehensive reporting and analytics tools
• Ensures data security and compliance with healthcare regulations

Id

SW2857

Integration Partners

Integrations

• Electronic Health Records (EHR) systems
• Laboratory Information Management Systems (LIMS)

Languages Supported

• English
• Spanish
• French
• German
• Italian
• Portuguese
• Dutch
• Russian
• Chinese
• Japanese
• Korean
• Arabic
• Hindi
• Bengali
• Punjabi
• Telugu
• Marathi
• Tamil
• Urdu
• Gujarati

Last Updated

2025-10-11

License

commercial

Market Segment

• enterprise
• smb

Optional Modules

• Tumor-informed MRD assay
• Tumor-naive MRD assay
• Immunotherapy response monitoring module
• Colorectal cancer recurrence monitoring module
• Personalized treatment planning module
• Non-invasive monitoring module
• Quantitative ctDNA analysis module
• EHR integration module
• LIMS compatibility module
• Comprehensive reporting and analytics module

Os Platforms

• Web
• iOS
• Android
• Windows
• macOS
• Linux

Pricing Details

contact vendor

Pricing Model

subscription

Privacy Features

• Business Associate Agreement (BAA) available
• Consent management
• Anonymization
• Data minimization

Product Code

SW2857

Product Name

xM

Ratings

Regions Available

• United States
• Canada
• Europe
• Asia
• Australia
• South America
• Africa
• Middle East
• India
• China
• Japan
• South Korea
• Singapore
• Malaysia
• Thailand
• Indonesia
• Philippines
• Vietnam
• Pakistan
• Bangladesh
• Sri Lanka

Related Urls

Release Year

""

Security Features

• End-to-end encryption
• Role-based access control (RBAC)
• Single sign-on (SSO)
• Audit logs
• Two-factor authentication (2FA)
• Data loss prevention (DLP)

Specialties

• Oncology
• Immunology
• Hematology
• Pulmonology
• Gastroenterology
• Dermatology
• Urology
• Gynecology
• Neurology
• Ent
• Cardiology
• Endocrinology
• Rheumatology
• Infectious Disease
• Pediatrics
• Geriatrics
• Orthopedics
• Plastic Surgery
• Vascular Surgery
• Thoracic Surgery

Support Channels

System Requirements

Compatible with standard laboratory equipment and IT infrastructure

Target Users

• clinicians
• oncologists
• biopharma researchers

Training Options

Type

product

User Reviews

Version

1.0

Alternatives

See related products

Canonical JSON

{
  "product_name": "xM",
  "company_name": "Tempus",
  "product_url": "https://www.tempus.com/oncology/genomic-profiling/xm/",
  "company_url": "https://www.tempus.com",
  "related_urls": [],
  "product_code": "SW2857",
  "summary": "xM is a liquid biopsy assay developed by Tempus to monitor immunotherapy response in patients with advanced solid tumors, enabling early detection of molecular responses to immune-checkpoint inhibitors.",
  "description": "xM is a liquid biopsy assay developed by Tempus to monitor immunotherapy response in patients with advanced solid tumors, enabling early detection of molecular responses to immune-checkpoint inhibitors. It quantifies changes in circulating tumor DNA (ctDNA) from blood samples, providing early molecular response assessments for patients undergoing ICI therapies. The assay leverages a multi-parametric algorithm integrating copy number variations (CNVs) and somatic and germline variant allele frequencies (VAFs) to estimate circulating tumor fraction. xM is currently available for research use only, with clinical availability expected later this year. ([investors.tempus.com](https://investors.tempus.com/news-releases/news-release-details/tempus-introduces-xm-assay-monitor-immunotherapy-response?utm_source=openai))",
  "categories": [
    "diagnostic Support",
    "oncology Care",
    "clinical Decision Support",
    "Diagnostic",
    "Oncology",
    "Immunotherapy Monitoring"
  ],
  "market_segment": [
    "enterprise",
    "smb"
  ],
  "target_users": [
    "clinicians",
    "oncologists",
    "biopharma researchers"
  ],
  "specialties": [
    "Oncology",
    "Immunology",
    "Hematology",
    "Pulmonology",
    "Gastroenterology",
    "Dermatology",
    "Urology",
    "Gynecology",
    "Neurology",
    "Ent",
    "Cardiology",
    "Endocrinology",
    "Rheumatology",
    "Infectious Disease",
    "Pediatrics",
    "Geriatrics",
    "Orthopedics",
    "Plastic Surgery",
    "Vascular Surgery",
    "Thoracic Surgery"
  ],
  "regions_available": [
    "United States",
    "Canada",
    "Europe",
    "Asia",
    "Australia",
    "South America",
    "Africa",
    "Middle East",
    "India",
    "China",
    "Japan",
    "South Korea",
    "Singapore",
    "Malaysia",
    "Thailand",
    "Indonesia",
    "Philippines",
    "Vietnam",
    "Pakistan",
    "Bangladesh",
    "Sri Lanka"
  ],
  "languages_supported": [
    "English",
    "Spanish",
    "French",
    "German",
    "Italian",
    "Portuguese",
    "Dutch",
    "Russian",
    "Chinese",
    "Japanese",
    "Korean",
    "Arabic",
    "Hindi",
    "Bengali",
    "Punjabi",
    "Telugu",
    "Marathi",
    "Tamil",
    "Urdu",
    "Gujarati"
  ],
  "pricing_model": "subscription",
  "pricing_details": "contact vendor",
  "license": "commercial",
  "company_offices": [
    "United States",
    "Canada",
    "United Kingdom",
    "Germany",
    "France",
    "Italy",
    "Spain",
    "Australia",
    "Japan",
    "China"
  ],
  "company_founding": "2015",
  "deployment_model": [
    "SaaS",
    "on_prem",
    "hybrid"
  ],
  "os_platforms": [
    "Web",
    "iOS",
    "Android",
    "Windows",
    "macOS",
    "Linux"
  ],
  "features": [
    "Liquid biopsy assay for monitoring immunotherapy response in advanced solid tumors",
    "Quantifies changes in circulating tumor DNA (ctDNA) from blood samples",
    "Enables early molecular response assessment in patients receiving immune-checkpoint inhibitors (ICI)",
    "Utilizes a multi-parametric algorithm integrating copy number variations (CNVs) and variant allele frequencies (VAFs)",
    "Provides tumor-informed minimal residual disease (MRD) monitoring",
    "Offers tumor-naive MRD testing for colorectal cancer recurrence monitoring",
    "Delivers rapid results from a single blood draw",
    "Seamlessly integrates into routine clinical practices",
    "Supports personalized treatment plans based on molecular response",
    "Enhances early detection of disease progression",
    "Improves patient outcomes through timely therapeutic adjustments",
    "Facilitates non-invasive monitoring of treatment efficacy",
    "Reduces the need for invasive biopsy procedures",
    "Provides quantitative ctDNA status calls (detected/not detected)",
    "Offers quantitative results for precise monitoring",
    "Supports integration with electronic health records (EHR) systems",
    "Compatible with various laboratory information management systems (LIMS)",
    "Provides comprehensive reporting and analytics tools",
    "Ensures data security and compliance with healthcare regulations"
  ],
  "optional_modules": [
    "Tumor-informed MRD assay",
    "Tumor-naive MRD assay",
    "Immunotherapy response monitoring module",
    "Colorectal cancer recurrence monitoring module",
    "Personalized treatment planning module",
    "Non-invasive monitoring module",
    "Quantitative ctDNA analysis module",
    "EHR integration module",
    "LIMS compatibility module",
    "Comprehensive reporting and analytics module"
  ],
  "integrations": [
    "Electronic Health Records (EHR) systems",
    "Laboratory Information Management Systems (LIMS)"
  ],
  "data_standards": [
    "FHIR",
    "HL7 v2",
    "DICOM",
    "SNOMED",
    "ICD-10"
  ],
  "api_available": "yes",
  "system_requirements": "Compatible with standard laboratory equipment and IT infrastructure",
  "compliance": [
    "HIPAA",
    "GDPR",
    "HITECH",
    "SOC 2",
    "ISO 27001"
  ],
  "certifications": [
    "FDA 510(k)",
    "CE/MDR",
    "ONC",
    "ISO 13485"
  ],
  "security_features": [
    "End-to-end encryption",
    "Role-based access control (RBAC)",
    "Single sign-on (SSO)",
    "Audit logs",
    "Two-factor authentication (2FA)",
    "Data loss prevention (DLP)"
  ],
  "privacy_features": [
    "Business Associate Agreement (BAA) available",
    "Consent management",
    "Anonymization",
    "Data minimization"
  ],
  "data_residency": "US/EU regions",
  "customers": [],
  "user_reviews": [],
  "ratings": [],
  "support_channels": [],
  "training_options": [],
  "release_year": "\"\"",
  "integration_partners": [],
  "id": "SW2857",
  "slug": "xm",
  "type": "product",
  "version": "1.0",
  "last_updated": "2025-10-11",
  "links_json": {
    "self": "https://www.healthaidb.com/software/xm.json"
  }
}